Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia
EC Attar, DJ DeAngelo, JG Supko, F D'Amato… - Clinical cancer …, 2008 - AACR
Purpose: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro. We
conducted this phase I study to determine if the proteasome inhibitor bortezomib could be …
conducted this phase I study to determine if the proteasome inhibitor bortezomib could be …
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms …
H Minderman, Y Zhou, KL O'Loughlin… - Cancer chemotherapy and …, 2007 - Springer
Purpose The proteasome inhibitor bortezomib may be effective in combination with
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …
Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell …
JE Romaguera, LE Fayad, P McLaughlin… - British journal of …, 2010 - Wiley Online Library
Mantle cell lymphoma (MCL) outcomes have improved over the last two decades; however,
late relapses occur. Bortezomib has shown single agent activity of 33% in relapsed MCL …
late relapses occur. Bortezomib has shown single agent activity of 33% in relapsed MCL …
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with …
JE Romaguera, M Wang, L Feng, LE Fayad… - Cancer, 2018 - Wiley Online Library
BACKGROUND Although the outcomes of patients with mantle cell lymphoma (MCL) have
improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory …
improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory …
Proteasome inhibitor bortezomib overcomes P‐gp‐mediated multidrug resistance in resistant leukemic cell lines
B Zheng, R Zhou, Y Gong, X Yang… - International journal of …, 2012 - Wiley Online Library
Introduction: To study the effect of bortezomib alone or in combination with daunorubicin
(DNR) on an mdr1 single‐factor drug‐resistant leukemia cell line K562/MDR1, a multifactor …
(DNR) on an mdr1 single‐factor drug‐resistant leukemia cell line K562/MDR1, a multifactor …
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma
P Moosmann, M Heizmann, N Kotrubczik… - Leukemia & …, 2010 - Taylor & Francis
Bendamustine was designed as a bifunctional anticancer compound combining an
alkylating and an antimetabolite function. It shows unique mechanisms of action and …
alkylating and an antimetabolite function. It shows unique mechanisms of action and …
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms …
M Hans, Y Zhou, L O'Loughlin Kieran… - Cancer Chemotherapy …, 2007 - search.proquest.com
Purpose The proteasome inhibitor bortezomib may be effective in combination with
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …